MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Avatud

SektorTervishoid

12.61 2.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.18

Max

12.73

Põhinäitajad
By Trading Economics
Sissetulek	-445K -19M
Müük	-3.2M 15M
Kasumimarginaal	-123.636
Töötajad	120
EBITDA	-883K -16M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+48.12% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-6.1M 364M
Eelmine avamishind	10.5
Eelmine sulgemishind	12.61

Uudiste sentiment

By Acuity

50%

177 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

5.04 / 5.44 Toetus ja vastupanu

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. jaan 2026, 23:49 UTC

Suurimad hinnamuutused turgudel

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. jaan 2026, 21:12 UTC

Suurimad hinnamuutused turgudel

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. jaan 2026, 20:29 UTC

Suurimad hinnamuutused turgudel

Chip Makers Gain After Trump Calls Off European Tariffs

21. jaan 2026, 20:04 UTC

Suurimad hinnamuutused turgudel

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. jaan 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. jaan 2026, 22:39 UTC

Tulu

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. jaan 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. jaan 2026, 21:19 UTC

Tulu

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. jaan 2026, 20:45 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. jaan 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. jaan 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. jaan 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. jaan 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. jaan 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. jaan 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. jaan 2026, 20:23 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. jaan 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. jaan 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Group Agrees to Buy Allfunds

21. jaan 2026, 20:08 UTC

Tulu

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. jaan 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. jaan 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. jaan 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. jaan 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. jaan 2026, 19:24 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. jaan 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. jaan 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

48.12% tõus

12 kuu keskmine prognoos

Keskmine 18.5 USD 48.12%

Kõrge 20 USD

Madal 17 USD

Põhineb 2 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.04 / 5.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

177 / 360 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.